Collaboration: Pfizer, Eyetech in deal for AMD, DME therapy

Article

New York-Pfizer Inc. and Eyetech Pharmaceuticals Inc. will jointly develop and commercialize Eyetech's pegaptanib sodium (Macugen) as a potential treatment for age-related macular degeneration (AMD) and diabetic macular edema (DME).

Recent Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Related Content
ChatGPT may have a future use in glaucoma

ChatGPT may have a future use in glaucoma

Article
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics

Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics

Podcast
Therapeutic in development to take on diabetic macular edema

Therapeutic in development to take on diabetic macular edema

Article
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics

Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention

Podcast
Ocugen completes dosing in subjects with GA secondary to dAMD in Phase 1/2 ArMaDa clinical trial of OCU410

Ocugen completes dosing in subjects with GA secondary to dAMD in Phase 1/2 ArMaDa clinical trial of OCU410

Article
Stress resilience–enhancing drugs: New class of small molecules holds promise

Stress resilience–enhancing drugs: New class of small molecules holds promise

Article
© 2024 MJH Life Sciences

All rights reserved.